

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934
(Amendment No.)*

_____ Cytoclonal Pharmaceuticals _____
(Name of Issuer)

_____ Common Stock _____
(Title of Class of Securities)

28282G105
(CUSIP Number)

Bruce Meyers c/o Janssen-Meyers Associates, L.P.
17 State Street, NY, NY 10004 (212) 742-4200
(Name, Address and Telephone Number Person Authorized to
Receive Notices and Communications)

_____ 7/1998 _____
(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G
to report the acquisition which is the
subject of this Schedule 13D, and is filing this schedule because of
Rule 13d-1(b)(3) or (4), check the
following box _____.

Check the following box if a fee is being paid with the statement _____.
(A fee is not required only if the
reporting person: (1) has a previous statement on file reporting
beneficial ownership of more than five
percent of the class of securities described in Item 1; and
(2) has filed no amendment subsequent thereto
reporting beneficial ownership of five percent or less of such class.)
(Sec Rule 13d-7.)

Note: Six copies of this statement, including all exhibits, should
be filed with the Commission. See Rule
13d-1(a) for other parties to whom copies are to be sent.

*The remainder of this cover page shall be filled out for a
reporting person's initial filing on this form with
respect to the subject class of securities, and for any subsequent

amendment containing information which
would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not
be deemed to be "filed" for the
purpose of Section 18 of the Securities Exchange Act of 1934 ("Act")
or otherwise subject to the liabilities
of that section of the Act but shall be subject to all other provisions
of the Act (however, see the Notes).

Bruce Meyers
S.S. or I.R.S. Identification No. of Above Person

2. Check the Appropriate Box if a Member of a Group (See Instructions before filling out)

a. _____ b. _____

3. SEC USE ONLY

4. Source of Funds (See instructions before filling out).

_____ Personal funds _____

5. Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e).

6. Citizenship or Place of Organization

_____ USA _____

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON
(Questions 7 - 10)

7. Sole Voting Power

_____ 1,186,615 _____

8. Shared Voting Power

9. Sole Dispositive Power

_____ 1,186,615 _____

10. Shared Dispositive Power

11. Aggregate Amount Beneficially Owned by Each Reporting Person

12. Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares
(See instructions before filling out)

13. Percent of Class Represented by Amount in Row (11)

_____ 11.73% _____

14. Type of Reporting Person (See instructions before filling out)

_____ Shareholder _____